Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
The purpose of this website is to inform healthcare professionals and members of the general public about Novo Nordisk and their products.
Information placed on this website is not intended as a substitute for consultation with your healthcare professional.
Date of preparation: December 2014
The Apis bull logo is a registered trademark of Novo Nordisk A/S